Form 4: Nurix Therapeutics Director, Lori Anne Kunkel, Acquires 25,000 Stock Options
SEC Form 4 Filing
Director Lori Anne Kunkel acquired 25,000 stock options in Nurix Therapeutics, Inc. on May 20, 2024.
Summary
- Lori Anne Kunkel, a director of Nurix Therapeutics, Inc., filed a Form 4 to report changes in beneficial ownership.
- On May 20, 2024, Kunkel acquired 25,000 stock options with an exercise price of $16.19.
- These options vest fully on the earlier of the next annual meeting of the Issuer's stockholders or May 20, 2025, contingent upon continued service to the Issuer.
- The options expire on May 19, 2034.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing regarding stock option grants, indicating a neutral sentiment.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the options.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors.
Stakeholder Impact
- The granting of stock options aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 05/20/2024 | Date of transaction: acquisition of 25,000 stock options. |
| 05/20/2025 | Vesting date of the stock options, contingent on continued service, or earlier at the next annual meeting. |
| 05/19/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.